menu
    • menu

    Company profile for Galmed Pharmaceuticals

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage biopharmaceutical company focused on the development of Aramchol™, liver-targeted stearoyl-coenzyme A desaturase‑1 (“SCD1ˮ) modulator, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis). We believe that our product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, whi...
    We are a clinical-stage biopharmaceutical company focused on the development of Aramchol™, liver-targeted stearoyl-coenzyme A desaturase‑1 (“SCD1ˮ) modulator, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis). We believe that our product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that constitutes a large unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Galmed PharmaceuticalsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    16 Tiomkin Street Tel Aviv, 6578317 Israel
    Telephone
    Telephone
    +972.3.693.8448
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://galmedpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed Issues CEO Letter To Shareholders
    Galmed Issues CEO Letter To Shareholders

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-issues-ceo-letter-to-shareholders-302629086.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Galmed Pharma Reveals Q3 2025 Financials & Business Update
    Galmed Pharma Reveals Q3 2025 Financials & Business Update

    26 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business-update-302626668.html

    PR NEWSWIRE
    26 Nov 2025
    Share Share
    Galmed Reports Significant AM-001 Study Results For Aramchol
    Galmed Reports Significant AM-001 Study Results For Aramchol

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-meaningful-top-line-results-from-am-001-study-of-aramchol-meglumine-302618567.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    Galmed Announces Top-line Results in Oncology MoA Studies
    Galmed Announces Top-line Results in Oncology MoA Studies

    17 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-top-line-results-in-oncology-moa-studies-a-3-drug-combination-of-aramchol-stivarga-and-metformin-significantly-enhanced-gi-tumor-cells-killing-in-vivo-and-in-vitro-302617120.html

    PR NEWSWIRE
    17 Nov 2025
    Share Share
    Galmed Pharmaceuticals Unveils Q2 2025 Financials and Business
    Galmed Pharmaceuticals Unveils Q2 2025 Financials and Business

    28 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business-update-302541005.html

    PR NEWSWIRE
    28 Aug 2025
    Share Share
    Galmed Boosts Capital Efficiency with Digital Asset Management
    Galmed Boosts Capital Efficiency with Digital Asset Management

    25 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-digital-asset-management-strategy-to-enhance-capital-efficiency-and-drive-shareholder-value-302537588.html

    PR NEWSWIRE
    25 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search